

RNA Drugs Global Market Insights 2026, Analysis and Forecast to 2031

<https://marketpublishers.com/r/RF3E6ED32F98EN.html>

Date: April 2026

Pages: 145

Price: US\$ 3,200.00 (Single User License)

ID: RF3E6ED32F98EN

Abstracts

RNA Drugs Market Summary

Introduction

The pharmaceutical landscape is undergoing a profound structural shift, transitioning from interventions that target downstream proteins to therapies that modulate upstream genetic messengers. RNA drugs represent a transformative class of therapeutics—encompassing messenger RNA (mRNA), antisense oligonucleotides (ASOs), and small interfering RNA (siRNA). By targeting the transcriptome directly, these modalities bypass the traditional limitations of the 'druggable proteome,' opening highly specific therapeutic corridors for rare genetic disorders, aggressive oncological indications, and complex infectious diseases.

Foundational therapies like Spinraza for spinal muscular atrophy and Patisiran (Onpattro) for hATTR amyloidosis established the clinical viability of modulating RNA. The sector recently witnessed a defining milestone that underscores its rapid evolution. On March 28, 2025, Alnylam Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of Qfitlia™ (fitusiran). As the sixth RNAi therapeutic discovered by Alnylam to achieve U.S. approval, fitusiran represents a paradigm shift in hematology. It is the first and only therapeutic designed to lower antithrombin (AT), actively promoting thrombin generation to rebalance hemostasis and prevent bleeds. This approval not only cements the commercial viability of RNA interference but also signals the modality's successful expansion beyond ultra-rare metabolic disorders into broader, high-impact clinical pathways.

Current market projections validate this clinical momentum. The global RNA drugs

market is projected to reach a valuation between \$13.2 billion and \$13.8 billion by 2026. Looking forward, the sector is positioned for aggressive, sustained expansion, with an estimated Compound Annual Growth Rate (CAGR) ranging from 13% to 15% through 2031. This trajectory is driven by the maturation of delivery technologies, an accelerating pipeline of clinical assets, and a strategic pivot among Tier-1 biopharmaceutical companies to secure oligonucleotide manufacturing capacity.

Regional Market Dynamics

The global commercialization of RNA therapeutics demonstrates highly asymmetrical regional adoption curves, dictated by healthcare infrastructure, intellectual property frameworks, and the availability of specialized cold-chain logistics.

North America

North America dictates the global tempo for RNA innovation and commercialization, capturing the primary share of both capital allocation and clinical trial volume. Estimated to grow at a localized trajectory of 12% to 14%, the region benefits from aggressive venture capitalization and highly structured regulatory pathways tailored for advanced therapy medicinal products (ATMPs). The U.S. market specifically is characterized by rapid early adoption, though manufacturers increasingly face headwinds from managed care organizations demanding robust pharmacoeconomic data to justify the high upfront costs of curative or long-acting RNA therapies. Value-based contracting and outcomes-based reimbursement models are rapidly becoming a mandatory component of the commercial strategy.

Europe

The European market presents a highly fragmented but lucrative landscape, with expected regional growth oscillating between 11% and 13%. Market penetration here is heavily reliant on navigating the stringent Health Technology Assessment (HTA) bodies. Countries like Germany and the UK exhibit rapid uptake for breakthrough orphan designations, whereas Southern and Eastern Europe experience delayed adoption due to rigid budget impact models. The European Medicines Agency (EMA) continues to refine its regulatory guidance regarding the environmental risk assessment of lipid nanoparticles and the long-term pharmacovigilance of synthetic oligonucleotides, creating a predictable, albeit rigorous, commercialization environment.

Asia-Pacific (APAC)

APAC represents the most dynamic frontier for RNA therapeutics, poised for an aggressive expansion rate estimated between 16% and 19%. This acceleration is driven by shifting demographic profiles, increasing healthcare expenditure, and a massive push toward indigenous biotechnology sovereignty. China is aggressively building a localized RNA value chain, moving rapidly from generic API manufacturing to proprietary LNP formulation and target discovery. Taiwan, China plays a highly strategic role in this regional ecosystem, serving as a critical node for advanced clinical trial operations, high-precision biotechnology manufacturing, and regional technology transfer. Japan continues to be a high-value market due to its rapidly aging population and favorable regulatory mechanisms for regenerative and genetic medicines.

South America

Growth in South America remains moderate, expected to range between 8% and 10%. The primary barrier to entry is the lack of specialized infrastructure required for ultra-cold chain logistics, historically necessary for early-generation mRNA formulations. However, the advent of stable, room-temperature siRNA therapies and subcutaneous administration profiles is lowering these structural barriers. Brazil remains the focal point, where market access is largely dictated by centralized public health tenders and government-backed technology transfer initiatives.

Middle East and Africa (MEA)

Projected to grow at 9% to 11%, the MEA region is characterized by stark internal polarization. The Gulf Cooperation Council (GCC) nations act as highly lucrative micro-markets, frequently engaging in early adoption of high-cost orphan RNA drugs through specialized government funding. Conversely, broader African markets remain largely untapped, awaiting the development of thermostable RNA formats and significantly highly differentiated pricing tiers to align with local healthcare economics.

Delivery Technology Segmentation: LNPs and GalNAc

The commercial viability of an RNA drug is inextricably linked to its delivery system. Naked RNA is rapidly degraded by endogenous nucleases and cannot cross cell membranes due to its high molecular weight and negative charge. Consequently, the intellectual property surrounding delivery vehicles is often more intensely contested than the RNA sequences themselves.

GalNAc (N-Acetylgalactosamine) Conjugates

GalNAc technology fundamentally revolutionized the siRNA landscape. By conjugating the RNA molecule to a trivalent GalNAc ligand, therapeutics gain highly specific, high-affinity targeting to the asialoglycoprotein receptor (ASGPR), which is abundantly and almost exclusively expressed on the surface of hepatocytes.

This technology affords several profound strategic advantages. First, it enables subcutaneous administration, transitioning RNA therapies from the hospital infusion center to the patient's home. Second, it offers an exceptional therapeutic index—the targeted delivery allows for massive dose reductions, virtually eliminating systemic toxicity. Finally, GalNAc conjugates exhibit extreme durability, allowing for dosing regimens of once every three to six months. This platform is the primary engine behind Alnylam's commercial dominance in liver-directed indications and represents the gold standard for treating hepatic-origin diseases.

Lipid Nanoparticles (LNPs)

While GalNAc dominates hepatocyte targeting, LNPs represent the vanguard of systemic and large-payload delivery, particularly for mRNA. An LNP is a highly complex multi-component system typically comprising an ionizable cationic lipid, a PEGylated lipid, cholesterol, and helper phospholipids. The ionizable lipid is the critical proprietary component, engineered to remain neutral in systemic circulation (minimizing toxicity) while becoming protonated in the acidic environment of the endosome, facilitating membrane disruption and the release of the RNA payload into the cytosol.

The strategic focus within the LNP segment is currently shifting toward extra-hepatic delivery. Next-generation LNPs are being rigorously engineered—via alterations in lipid chemistry and the addition of targeting ligands—to bypass the liver sink effect and deliver RNA to the central nervous system (CNS), skeletal muscle, and tumor microenvironments. The complexity of LNP formulation creates significant manufacturing barriers, acting as a robust competitive moat for early innovators.

Value Chain & Supply Chain Analysis

The structural architecture of the RNA drugs value chain is highly specialized, demanding precision chemistry and engineering capabilities that drastically differ from traditional small molecule or biologics manufacturing.

Target Discovery and Sequence Design

The genesis of the value chain relies heavily on computational biology. Companies utilize advanced bioinformatics, increasingly augmented by machine learning, to identify optimal binding sites on target mRNA. The objective is to design sequences that maximize on-target gene silencing or expression while rigorously minimizing off-target homology that could trigger unintended phenotypic responses.

Raw Material Sourcing

RNA synthesis is voraciously dependent on highly specialized raw materials. The foundation requires customized nucleoside phosphoramidites, modified to resist nuclease degradation (e.g., 2'-O-methyl or 2'-fluoro modifications). Furthermore, the synthesis of proprietary ionizable lipids for LNPs relies on a narrow base of highly specialized specialty chemical suppliers. Consolidation and supply chain resilience within this node have become board-level priorities following recent global supply chain disruptions.

Oligonucleotide Synthesis and Manufacturing

Unlike monoclonal antibodies grown in bioreactors, RNA therapeutics are typically manufactured via solid-phase chemical synthesis. This process requires iterative cycles of deprotection, coupling, capping, and oxidation. The primary bottleneck in the current industry is scale. As RNA drugs transition from treating rare orphan diseases (requiring kilograms of API) to broad cardiometabolic conditions (requiring metric tons), the physical infrastructure for synthesis, cleavage, and downstream chromatography purification is being strained.

Formulation and Fill-Finish

Integrating the synthesized RNA with its delivery vehicle is an intricate biophysical process. For LNPs, this requires highly calibrated microfluidic mixing to ensure uniform nanoparticle size and encapsulation efficiency. The fill-finish stage must often occur under stringent aseptic conditions, and for certain modalities, requires immediate entry into a rigorous cold-chain logistics network.

Commercialization and Patient Access

The final node involves navigating highly complex reimbursement landscapes. Given

the frequently high acquisition costs of genetic medicines, commercialization teams must deploy innovative value-based agreements, engaging with payers to amortize costs based on longitudinal clinical outcomes rather than point-of-sale volume.

Competitive Landscape

The market is characterized by a concentrated group of pure-play pioneers, an aggressive influx of Tier-1 pharmaceutical conglomerates, and an expanding cohort of agile, specialized innovators. Strategic positioning heavily depends on the control of proprietary delivery platforms and the ability to scale manufacturing.

The Vanguard Pioneers

Alnylam Pharmaceuticals Inc. occupies the apex of the competitive hierarchy. As the undisputed pioneer of RNA interference, Alnylam possesses the most validated and commercially successful pipeline in the industry. The recent FDA approval of fitusiran (Qfitlia™) explicitly demonstrates the company's ability to pivot its validated GalNAc-siRNA technology from metabolic disorders into complex hematological pathways. Arrowhead Pharmaceuticals Inc. operates as a formidable counterweight, utilizing its proprietary TRIM™ platform to rapidly generate a deep pipeline of targeted RNAi therapeutics. Arrowhead's strategic aggression in targeting both hepatic and extra-hepatic indications (such as pulmonary diseases) positions it as a critical pillar in the sector.

Multinational Pharmaceutical Integrators

Recognizing the existential threat and massive upside of genetic medicines, major pharmaceutical entities have aggressively entered the space, primarily through strategic licensing, acquisitions, and heavy R&D subsidization. Takeda Pharmaceutical Company Limited has deeply integrated RNA assets into its core portfolio, particularly leveraging its vast footprint in gastroenterology and rare diseases to accelerate the commercialization of partnered assets. Amgen Inc. approaches the market with immense capital leverage, focusing heavily on integrating RNA therapeutics into its cardiovascular and oncology portfolios, frequently utilizing its massive global commercial infrastructure to out-compete smaller biotech firms in late-stage clinical trials and market access negotiations.

Next-Generation Platform Innovators

A crucial segment of the market consists of companies engineering structural solutions to existing RNA limitations. Silence Therapeutics plc and WAVE Life Sciences Ltd. are redefining molecular precision. WAVE, in particular, leverages its PRISM platform to produce stereopure oligonucleotides, theoretically offering superior pharmacokinetic profiles and reduced off-target toxicity compared to traditional stereorandom mixtures. Arbutus Biopharma Corporation remains a pivotal player, not necessarily through a vast commercial pipeline, but via its foundational intellectual property surrounding LNP delivery architecture, making it a central figure in ongoing industry IP licensing and litigation.

Regional and Emerging Challengers

The geographic diversification of the industry is led by entities like Asclepis Pharma Inc. and Sirnaomics Inc., which are rapidly advancing pipelines within the APAC ecosystem. Sirnaomics is notably pioneering the use of polypeptide nanoparticle (PNP) technology for oncology and fibrotic diseases, challenging the LNP hegemony. OliX Pharmaceuticals Inc. leverages its proprietary cell-penetrating asymmetric siRNA (cp-asiRNA) to target local administration routes, such as ocular and dermal indications, effectively bypassing the complexities of systemic delivery. Biomics Biotechnologies Co. Ltd. adds further depth to the Asian biotech surge, focusing on accelerated target validation and local manufacturing integration.

Niche Therapeutic Specialists

Companies such as Sylentis S.A. focus heavily on localized delivery, particularly ocular indications where the blood-ocular barrier provides a contained environment for RNA interference. Phio Pharmaceuticals Corp. is driving innovation at the intersection of RNAi and immuno-oncology, utilizing its INTASYL platform to silence immunosuppressive genes directly within the tumor microenvironment. Arcturus Therapeutics Holdings Inc. continues to push the boundaries of self-amplifying mRNA (sa-mRNA) and LNP delivery, aiming to drastically reduce the required dose for vaccines and therapeutics. Adhera Therapeutics Inc. and Bio-Path Holdings Inc. are strategically maneuvering within niche oncological and systemic disease targets, seeking to optimize specific delivery vectors to carve out defensible market share against larger incumbents.

Opportunities & Challenges

The trajectory of the RNA drugs sector is defined by a fierce interplay between

technological breakthroughs and profound logistical constraints.

Strategic Opportunities

The most lucrative frontier in the current landscape is the conquest of extra-hepatic delivery. The industry is aggressively engineering novel delivery vectors—including antibody-oligonucleotide conjugates (AOCs) and peptide-driven nanoparticles—designed to penetrate the blood-brain barrier for neurodegenerative diseases or achieve high-efficiency transfection in skeletal muscle for dystrophies.

Simultaneously, the therapeutic aperture is widening. The successful validation of RNA therapeutics in ultra-rare orphan indications has built the safety databases required to target highly prevalent chronic diseases. The pipeline shift toward hypertension, hypercholesterolemia, and chronic hepatitis B represents an opportunity to transition RNA drugs from niche, high-margin products into mass-market pharmaceutical blockbusters. Furthermore, the combination of RNA drugs with standard-of-care small molecules or monoclonal antibodies offers a pathway to synergistic efficacy, particularly in complex, multi-pathway oncological indications.

Market Challenges

Despite the clinical momentum, severe structural bottlenecks persist. The global capacity for oligonucleotide synthesis is actively strained. Scaling production to meet the demands of prevalent diseases requires entirely new chemical engineering paradigms, as current solid-phase synthesis yields are economically and physically challenging at the metric-ton scale.

Intellectual property friction serves as a constant drag on capital efficiency. The foundational patents surrounding LNP composition and nucleotide modification are heavily fragmented, resulting in an intricate web of cross-licensing dependencies and aggressive litigation that can delay commercialization.

Finally, the sector faces a highly volatile market access environment. Healthcare systems globally are struggling to absorb the budgetary impact of high-cost genetic medicines. Manufacturers must navigate profound resistance from payers, requiring heavy investments in real-world evidence generation and the implementation of complex, risk-sharing financial models to secure reimbursement and ensure patient access.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

- 3.1 Research Scope
- 3.2 Research Sources
 - 3.2.1 Data Sources
 - 3.2.2 Assumptions
- 3.3 Research Method

CHAPTER 4 MARKET LANDSCAPE

- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

- 6.1 Upstream/Suppliers Analysis
- 6.2 RNA Drugs Analysis
 - 6.2.1 Technology Analysis
 - 6.2.2 Cost Analysis
 - 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 TRADING ANALYSIS

- 8.1 Export of RNA Drugs by Region
- 8.2 Import of RNA Drugs by Region
- 8.3 Balance of Trade

CHAPTER 9 HISTORICAL AND FORECAST RNA DRUGS MARKET IN NORTH AMERICA (2021-2031)

- 9.1 RNA Drugs Market Size
- 9.2 RNA Drugs Demand by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Type Segmentation and Price
- 9.5 Key Countries Analysis
 - 9.5.1 United States
 - 9.5.2 Canada
 - 9.5.3 Mexico

CHAPTER 10 HISTORICAL AND FORECAST RNA DRUGS MARKET IN SOUTH AMERICA (2021-2031)

- 10.1 RNA Drugs Market Size
- 10.2 RNA Drugs Demand by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Type Segmentation and Price
- 10.5 Key Countries Analysis
 - 10.5.1 Brazil
 - 10.5.2 Argentina
 - 10.5.3 Chile
 - 10.5.4 Peru

CHAPTER 11 HISTORICAL AND FORECAST RNA DRUGS MARKET IN ASIA & PACIFIC (2021-2031)

- 11.1 RNA Drugs Market Size
- 11.2 RNA Drugs Demand by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Type Segmentation and Price
- 11.5 Key Countries Analysis
 - 11.5.1 China
 - 11.5.2 India
 - 11.5.3 Japan
 - 11.5.4 South Korea
 - 11.5.5 Southeast Asia
 - 11.5.6 Australia & New Zealand

CHAPTER 12 HISTORICAL AND FORECAST RNA DRUGS MARKET IN EUROPE (2021-2031)

- 12.1 RNA Drugs Market Size
- 12.2 RNA Drugs Demand by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Type Segmentation and Price
- 12.5 Key Countries Analysis
 - 12.5.1 Germany
 - 12.5.2 France
 - 12.5.3 United Kingdom
 - 12.5.4 Italy
 - 12.5.5 Spain
 - 12.5.6 Belgium
 - 12.5.7 Netherlands
 - 12.5.8 Austria
 - 12.5.9 Poland
 - 12.5.10 North Europe

CHAPTER 13 HISTORICAL AND FORECAST RNA DRUGS MARKET IN MEA (2021-2031)

- 13.1 RNA Drugs Market Size
- 13.2 RNA Drugs Demand by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Type Segmentation and Price
- 13.5 Key Countries Analysis

- 13.5.1 Egypt
- 13.5.2 Israel
- 13.5.3 South Africa
- 13.5.4 Gulf Cooperation Council Countries
- 13.5.5 Turkey

CHAPTER 14 SUMMARY FOR GLOBAL RNA DRUGS MARKET (2021-2026)

- 14.1 RNA Drugs Market Size
- 14.2 RNA Drugs Demand by End Use
- 14.3 Competition by Players/Suppliers
- 14.4 Type Segmentation and Price

CHAPTER 15 GLOBAL RNA DRUGS MARKET FORECAST (2026-2031)

- 15.1 RNA Drugs Market Size Forecast
- 15.2 RNA Drugs Demand Forecast
- 15.3 Competition by Players/Suppliers
- 15.4 Type Segmentation and Price Forecast

CHAPTER 16 ANALYSIS OF GLOBAL KEY VENDORS

- 16.1 Alnylam Pharmaceuticals Inc.
 - 16.1.1 Company Profile
 - 16.1.2 Main Business and RNA Drugs Information
 - 16.1.3 SWOT Analysis of Alnylam Pharmaceuticals Inc.
 - 16.1.4 Alnylam Pharmaceuticals Inc. RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 16.2 Takeda Pharmaceutical Company Limited
 - 16.2.1 Company Profile
 - 16.2.2 Main Business and RNA Drugs Information
 - 16.2.3 SWOT Analysis of Takeda Pharmaceutical Company Limited
 - 16.2.4 Takeda Pharmaceutical Company Limited RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 16.3 Adhera Therapeutics Inc.
 - 16.3.1 Company Profile
 - 16.3.2 Main Business and RNA Drugs Information
 - 16.3.3 SWOT Analysis of Adhera Therapeutics Inc.
 - 16.3.4 Adhera Therapeutics Inc. RNA Drugs Sales, Revenue, Price and Gross Margin

(2021-2026)

16.4 Arrowhead Pharmaceuticals Inc.

16.4.1 Company Profile

16.4.2 Main Business and RNA Drugs Information

16.4.3 SWOT Analysis of Arrowhead Pharmaceuticals Inc.

16.4.4 Arrowhead Pharmaceuticals Inc. RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

16.5 Silence Therapeutics plc

16.5.1 Company Profile

16.5.2 Main Business and RNA Drugs Information

16.5.3 SWOT Analysis of Silence Therapeutics plc

16.5.4 Silence Therapeutics plc RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

16.6 Arbutus Biopharma Corporation

16.6.1 Company Profile

16.6.2 Main Business and RNA Drugs Information

16.6.3 SWOT Analysis of Arbutus Biopharma Corporation

16.6.4 Arbutus Biopharma Corporation RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

16.7 Sylentis S.A.

16.7.1 Company Profile

16.7.2 Main Business and RNA Drugs Information

16.7.3 SWOT Analysis of Sylentis S.A.

16.7.4 Sylentis S.A. RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

16.8 WAVE Life Sciences Ltd.

16.8.1 Company Profile

16.8.2 Main Business and RNA Drugs Information

16.8.3 SWOT Analysis of WAVE Life Sciences Ltd.

16.8.4 WAVE Life Sciences Ltd. RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

16.9 Ascletois Pharma Inc.

16.9.1 Company Profile

16.9.2 Main Business and RNA Drugs Information

16.9.3 SWOT Analysis of Ascletois Pharma Inc.

16.9.4 Ascletois Pharma Inc. RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

16.10 Biomics Biotechnologies Co. Ltd.

16.10.1 Company Profile

16.10.2 Main Business and RNA Drugs Information

16.10.3 SWOT Analysis of Biomics Biotechnologies Co. Ltd.

16.10.4 Biomics Biotechnologies Co. Ltd. RNA Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

Please ask for sample pages for full companies list

Tables & Figures

TABLES AND FIGURES

Table Abbreviation and Acronyms List
Table Research Scope of RNA Drugs Report
Table Data Sources of RNA Drugs Report
Table Major Assumptions of RNA Drugs Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure RNA Drugs Picture
Table RNA Drugs Classification
Table RNA Drugs Applications List
Table Drivers of RNA Drugs Market
Table Restraints of RNA Drugs Market
Table Opportunities of RNA Drugs Market
Table Threats of RNA Drugs Market
Table Raw Materials Suppliers List
Table Different Production Methods of RNA Drugs
Table Cost Structure Analysis of RNA Drugs
Table Key End Users List
Table Latest News of RNA Drugs Market
Table Merger and Acquisition List
Table Planned/Future Project of RNA Drugs Market
Table Policy of RNA Drugs Market
Table 2021-2031 Regional Export of RNA Drugs
Table 2021-2031 Regional Import of RNA Drugs
Table 2021-2031 Regional Trade Balance
Figure 2021-2031 Regional Trade Balance
Table 2021-2031 North America RNA Drugs Market Size and Market Volume List
Figure 2021-2031 North America RNA Drugs Market Size and CAGR
Figure 2021-2031 North America RNA Drugs Market Volume and CAGR
Table 2021-2031 North America RNA Drugs Demand List by Application
Table 2021-2026 North America RNA Drugs Key Players Sales List
Table 2021-2026 North America RNA Drugs Key Players Market Share List
Table 2021-2031 North America RNA Drugs Demand List by Type
Table 2021-2026 North America RNA Drugs Price List by Type
Table 2021-2031 United States RNA Drugs Market Size and Market Volume List
Table 2021-2031 United States RNA Drugs Import & Export List

Table 2021-2031 Canada RNA Drugs Market Size and Market Volume List
Table 2021-2031 Canada RNA Drugs Import & Export List
Table 2021-2031 Mexico RNA Drugs Market Size and Market Volume List
Table 2021-2031 Mexico RNA Drugs Import & Export List
Table 2021-2031 South America RNA Drugs Market Size and Market Volume List
Figure 2021-2031 South America RNA Drugs Market Size and CAGR
Figure 2021-2031 South America RNA Drugs Market Volume and CAGR
Table 2021-2031 South America RNA Drugs Demand List by Application
Table 2021-2026 South America RNA Drugs Key Players Sales List
Table 2021-2026 South America RNA Drugs Key Players Market Share List
Table 2021-2031 South America RNA Drugs Demand List by Type
Table 2021-2026 South America RNA Drugs Price List by Type
Table 2021-2031 Brazil RNA Drugs Market Size and Market Volume List
Table 2021-2031 Brazil RNA Drugs Import & Export List
Table 2021-2031 Argentina RNA Drugs Market Size and Market Volume List
Table 2021-2031 Argentina RNA Drugs Import & Export List
Table 2021-2031 Chile RNA Drugs Market Size and Market Volume List
Table 2021-2031 Chile RNA Drugs Import & Export List
Table 2021-2031 Peru RNA Drugs Market Size and Market Volume List
Table 2021-2031 Peru RNA Drugs Import & Export List
Table 2021-2031 Asia & Pacific RNA Drugs Market Size and Market Volume List
Figure 2021-2031 Asia & Pacific RNA Drugs Market Size and CAGR
Figure 2021-2031 Asia & Pacific RNA Drugs Market Volume and CAGR
Table 2021-2031 Asia & Pacific RNA Drugs Demand List by Application
Table 2021-2026 Asia & Pacific RNA Drugs Key Players Sales List
Table 2021-2026 Asia & Pacific RNA Drugs Key Players Market Share List
Table 2021-2031 Asia & Pacific RNA Drugs Demand List by Type
Table 2021-2026 Asia & Pacific RNA Drugs Price List by Type
Table 2021-2031 China RNA Drugs Market Size and Market Volume List
Table 2021-2031 China RNA Drugs Import & Export List
Table 2021-2031 India RNA Drugs Market Size and Market Volume List
Table 2021-2031 India RNA Drugs Import & Export List
Table 2021-2031 Japan RNA Drugs Market Size and Market Volume List
Table 2021-2031 Japan RNA Drugs Import & Export List
Table 2021-2031 South Korea RNA Drugs Market Size and Market Volume List
Table 2021-2031 South Korea RNA Drugs Import & Export List
Table 2021-2031 Southeast Asia RNA Drugs Market Size List
Table 2021-2031 Southeast Asia RNA Drugs Market Volume List
Table 2021-2031 Southeast Asia RNA Drugs Import List

Table 2021-2031 Southeast Asia RNA Drugs Export List
Table 2021-2031 Australia & New Zealand RNA Drugs Market Size and Market Volume List
Table 2021-2031 Australia & New Zealand RNA Drugs Import & Export List
Table 2021-2031 Europe RNA Drugs Market Size and Market Volume List
Figure 2021-2031 Europe RNA Drugs Market Size and CAGR
Figure 2021-2031 Europe RNA Drugs Market Volume and CAGR
Table 2021-2031 Europe RNA Drugs Demand List by Application
Table 2021-2026 Europe RNA Drugs Key Players Sales List
Table 2021-2026 Europe RNA Drugs Key Players Market Share List
Table 2021-2031 Europe RNA Drugs Demand List by Type
Table 2021-2026 Europe RNA Drugs Price List by Type
Table 2021-2031 Germany RNA Drugs Market Size and Market Volume List
Table 2021-2031 Germany RNA Drugs Import & Export List
Table 2021-2031 France RNA Drugs Market Size and Market Volume List
Table 2021-2031 France RNA Drugs Import & Export List
Table 2021-2031 United Kingdom RNA Drugs Market Size and Market Volume List
Table 2021-2031 United Kingdom RNA Drugs Import & Export List
Table 2021-2031 Italy RNA Drugs Market Size and Market Volume List
Table 2021-2031 Italy RNA Drugs Import & Export List
Table 2021-2031 Spain RNA Drugs Market Size and Market Volume List
Table 2021-2031 Spain RNA Drugs Import & Export List
Table 2021-2031 Belgium RNA Drugs Market Size and Market Volume List
Table 2021-2031 Belgium RNA Drugs Import & Export List
Table 2021-2031 Netherlands RNA Drugs Market Size and Market Volume List
Table 2021-2031 Netherlands RNA Drugs Import & Export List
Table 2021-2031 Austria RNA Drugs Market Size and Market Volume List
Table 2021-2031 Austria RNA Drugs Import & Export List
Table 2021-2031 Poland RNA Drugs Market Size and Market Volume List
Table 2021-2031 Poland RNA Drugs Import & Export List
Table 2021-2031 North Europe RNA Drugs Market Size and Market Volume List
Table 2021-2031 North Europe RNA Drugs Import & Export List
Table 2021-2031 MEA RNA Drugs Market Size and Market Volume List
Figure 2021-2031 MEA RNA Drugs Market Size and CAGR
Figure 2021-2031 MEA RNA Drugs Market Volume and CAGR
Table 2021-2031 MEA RNA Drugs Demand List by Application
Table 2021-2026 MEA RNA Drugs Key Players Sales List
Table 2021-2026 MEA RNA Drugs Key Players Market Share List
Table 2021-2031 MEA RNA Drugs Demand List by Type

Table 2021-2026 MEA RNA Drugs Price List by Type
Table 2021-2031 Egypt RNA Drugs Market Size and Market Volume List
Table 2021-2031 Egypt RNA Drugs Import & Export List
Table 2021-2031 Israel RNA Drugs Market Size and Market Volume List
Table 2021-2031 Israel RNA Drugs Import & Export List
Table 2021-2031 South Africa RNA Drugs Market Size and Market Volume List
Table 2021-2031 South Africa RNA Drugs Import & Export List
Table 2021-2031 Gulf Cooperation Council Countries RNA Drugs Market Size and Market Volume List
Table 2021-2031 Gulf Cooperation Council Countries RNA Drugs Import & Export List
Table 2021-2031 Turkey RNA Drugs Market Size and Market Volume List
Table 2021-2031 Turkey RNA Drugs Import & Export List
Table 2021-2026 Global RNA Drugs Market Size List by Region
Table 2021-2026 Global RNA Drugs Market Size Share List by Region
Table 2021-2026 Global RNA Drugs Market Volume List by Region
Table 2021-2026 Global RNA Drugs Market Volume Share List by Region
Table 2021-2026 Global RNA Drugs Demand List by Application
Table 2021-2026 Global RNA Drugs Demand Market Share List by Application
Table 2021-2026 Global RNA Drugs Key Vendors Sales List
Table 2021-2026 Global RNA Drugs Key Vendors Sales Share List
Figure 2021-2026 Global RNA Drugs Market Volume and Growth Rate
Table 2021-2026 Global RNA Drugs Key Vendors Revenue List
Figure 2021-2026 Global RNA Drugs Market Size and Growth Rate
Table 2021-2026 Global RNA Drugs Key Vendors Revenue Share List
Table 2021-2026 Global RNA Drugs Demand List by Type
Table 2021-2026 Global RNA Drugs Demand Market Share List by Type
Table 2021-2026 Regional RNA Drugs Price List
Table 2026-2031 Global RNA Drugs Market Size List by Region
Table 2026-2031 Global RNA Drugs Market Size Share List by Region
Table 2026-2031 Global RNA Drugs Market Volume List by Region
Table 2026-2031 Global RNA Drugs Market Volume Share List by Region
Table 2026-2031 Global RNA Drugs Demand List by Application
Table 2026-2031 Global RNA Drugs Demand Market Share List by Application
Table 2026-2031 Global RNA Drugs Key Vendors Sales List
Table 2026-2031 Global RNA Drugs Key Vendors Sales Share List
Figure 2026-2031 Global RNA Drugs Market Volume and Growth Rate
Table 2026-2031 Global RNA Drugs Key Vendors Revenue List
Figure 2026-2031 Global RNA Drugs Market Size and Growth Rate
Table 2026-2031 Global RNA Drugs Key Vendors Revenue Share List

Table 2026-2031 Global RNA Drugs Demand List by Type

Table 2026-2031 Global RNA Drugs Demand Market Share List by Type

Table 2026-2031 RNA Drugs Regional Price List

Table Alnylam Pharmaceuticals Inc. Information

Table SWOT Analysis of Alnylam Pharmaceuticals Inc.

Table 2021-2026 Alnylam Pharmaceuticals Inc. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Alnylam Pharmaceuticals Inc. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Alnylam Pharmaceuticals Inc. RNA Drugs Market Share

Table Takeda Pharmaceutical Company Limited Information

Table SWOT Analysis of Takeda Pharmaceutical Company Limited

Table 2021-2026 Takeda Pharmaceutical Company Limited RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Takeda Pharmaceutical Company Limited RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Takeda Pharmaceutical Company Limited RNA Drugs Market Share

Table Adhera Therapeutics Inc. Information

Table SWOT Analysis of Adhera Therapeutics Inc.

Table 2021-2026 Adhera Therapeutics Inc. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Adhera Therapeutics Inc. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Adhera Therapeutics Inc. RNA Drugs Market Share

Table Arrowhead Pharmaceuticals Inc. Information

Table SWOT Analysis of Arrowhead Pharmaceuticals Inc.

Table 2021-2026 Arrowhead Pharmaceuticals Inc. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Arrowhead Pharmaceuticals Inc. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Arrowhead Pharmaceuticals Inc. RNA Drugs Market Share

Table Silence Therapeutics plc Information

Table SWOT Analysis of Silence Therapeutics plc

Table 2021-2026 Silence Therapeutics plc RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Silence Therapeutics plc RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Silence Therapeutics plc RNA Drugs Market Share

Table Arbutus Biopharma Corporation Information

Table SWOT Analysis of Arbutus Biopharma Corporation

Table 2021-2026 Arbutus Biopharma Corporation RNA Drugs Sale Volume Price Cost

Revenue

Figure 2021-2026 Arbutus Biopharma Corporation RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Arbutus Biopharma Corporation RNA Drugs Market Share

Table Sylentis S.A. Information

Table SWOT Analysis of Sylentis S.A.

Table 2021-2026 Sylentis S.A. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Sylentis S.A. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Sylentis S.A. RNA Drugs Market Share

Table WAVE Life Sciences Ltd. Information

Table SWOT Analysis of WAVE Life Sciences Ltd.

Table 2021-2026 WAVE Life Sciences Ltd. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 WAVE Life Sciences Ltd. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 WAVE Life Sciences Ltd. RNA Drugs Market Share

Table Ascletois Pharma Inc. Information

Table SWOT Analysis of Ascletois Pharma Inc.

Table 2021-2026 Ascletois Pharma Inc. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Ascletois Pharma Inc. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Ascletois Pharma Inc. RNA Drugs Market Share

Table Biomics Biotechnologies Co. Ltd. Information

Table SWOT Analysis of Biomics Biotechnologies Co. Ltd.

Table 2021-2026 Biomics Biotechnologies Co. Ltd. RNA Drugs Sale Volume Price Cost Revenue

Figure 2021-2026 Biomics Biotechnologies Co. Ltd. RNA Drugs Sale Volume and Growth Rate

Figure 2021-2026 Biomics Biotechnologies Co. Ltd. RNA Drugs Market Share

.....

I would like to order

Product name: RNA Drugs Global Market Insights 2026, Analysis and Forecast to 2031

Product link: <https://marketpublishers.com/r/RF3E6ED32F98EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF3E6ED32F98EN.html>